Antibody against secreted n-terminal peptide of gpc3 present in blood
CA 2801911 A1 · Owner: Chugai Seiyaku Kabushiki Kaisha · Inventors: Ito, Yukio; Ohizumi, Iwao; Midorikawa, Yutaka
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same which can disrupt cells, in particular cancer cells. Specifically, the invention relates to an isolated antibody that binds to an N-terminal peptide of glypican-3 (GPC3).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 4, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.